These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19440216)

  • 1. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML.
    Korver W; Zhao X; Singh S; Pardoux C; Zhao J; Guzman ML; Sen S; Yonkovich S; Liu S; Zhan X; Tomasevic N; Zhou C; Gros D; Jordan CT; Gotlib J; Hsi ED; Abo A
    Leukemia; 2009 Sep; 23(9):1587-97. PubMed ID: 19440216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.
    Zhao X; Singh S; Pardoux C; Zhao J; Hsi ED; Abo A; Korver W
    Haematologica; 2010 Jan; 95(1):71-8. PubMed ID: 19648166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the ability of monoclonal antibodies to selectively mediate complement-dependent cytotoxicity of human myelogenous leukemia blast cells.
    Ball ED; Kadushin JM; Schacter B; Fanger MW
    J Immunol; 1982 Mar; 128(3):1476-81. PubMed ID: 6948897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
    Tettamanti S; Magnani CF; Biondi A; Biagi E
    Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells.
    Konopleva M; Estrov Z; Zhao S; Andreeff M; Mehta K
    J Immunol; 1998 Nov; 161(9):4702-8. PubMed ID: 9794400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-producing human-human hybridomas. III. Derivation and characterization of two antibodies with specificity for human myeloid cells.
    Andreasen RB; Olsson L
    J Immunol; 1986 Aug; 137(3):1083-90. PubMed ID: 3459756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects.
    White S; Taetle R; Seligman PA; Rutherford M; Trowbridge IS
    Cancer Res; 1990 Oct; 50(19):6295-301. PubMed ID: 2400993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
    Ågerstam H; Karlsson C; Hansen N; Sandén C; Askmyr M; von Palffy S; Högberg C; Rissler M; Wunderlich M; Juliusson G; Richter J; Sjöström K; Bhatia R; Mulloy JC; Järås M; Fioretos T
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10786-91. PubMed ID: 26261316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression.
    Saito Y; Nakahata S; Yamakawa N; Kaneda K; Ichihara E; Suekane A; Morishita K
    Leukemia; 2011 Jun; 25(6):921-31. PubMed ID: 21394097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody dependent cellular cytotoxicity and complement mediated cytotoxicity on leukemic cells mediated by anti K562 monoclonal antibodies.
    Tatake RJ; Maniar HS; Chiplunkar SV; Somasundaram R; Amin MK; Saikia T; Gangal SG
    J Clin Lab Immunol; 1990 Feb; 31(2):87-91. PubMed ID: 1966990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IREM-1 is a novel inhibitory receptor expressed by myeloid cells.
    Alvarez-Errico D; Aguilar H; Kitzig F; Brckalo T; Sayós J; López-Botet M
    Eur J Immunol; 2004 Dec; 34(12):3690-701. PubMed ID: 15549731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
    Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
    Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.
    Rosnet O; Bühring HJ; Marchetto S; Rappold I; Lavagna C; Sainty D; Arnoulet C; Chabannon C; Kanz L; Hannum C; Birnbaum D
    Leukemia; 1996 Feb; 10(2):238-48. PubMed ID: 8637232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of a novel immune receptor restricted to the monocytic lineage.
    Aguilar H; Alvarez-Errico D; García-Montero AC; Orfao A; Sayós J; López-Botet M
    J Immunol; 2004 Dec; 173(11):6703-11. PubMed ID: 15557162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
    Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
    Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.